Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas

ClinicalTrials.gov ID: NCT01078922

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01078922. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Open-label Study of Single Agent Ofatumumab in Patients With Relapsed and/or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase II open label study that looks at the efficacy and toxicity of Ofatumumab monotherapy in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). Patients will receive weekly infusions of Ofatumumab of 1000 mg each for 8 weeks (induction phase) followed by continuing the study drugs every other week in subsequent cycles (maintenance phase). Each 4 weeks of therapy will be calculated as one cycle. Treatment will continue until disease progression, toxicity, patient's withdrawal, or investigator's discretion.

Study identification

NCT ID: NCT01078922
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Oncology Specialists, S.C.; Other
Enrollment: 11 participants

Conditions and interventions

Conditions

Non-Hodgkin Lymphomas

Interventions

Ofatumumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 2010 (Type not available)
Primary completion: Oct 2013 (Actual)
Completion: Oct 2013 (Actual)
Last update posted: Jul 16, 2014

2010 – 2013

United States locations

U.S. sites: 3
U.S. states: 1
U.S. cities: 3

Facility	City	State	ZIP	Site status
University of Illinois at Chicago	Chicago	Illinois	60612	—
Oncology Specialists, S.C	Niles	Illinois	60714	—
Oncology Specialists, S.C.	Park Ridge	Illinois	60068	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01078922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 16, 2014 · Synced Nov 14, 2026